Eli Lilly to end 2024 among best in Big Pharma; Novo among worst

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo Nordisk (NVO), its closest rival in the lucrative obesity drug market, falls behind amid